Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7445482 + peginterferon alfa-2a + nucleos(t)ide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
Combination therapy including **RO7445482** (a GalNAc-conjugated short-interfering RNA that targets hepatitis B viral gene expression by binding to the S open reading frame), **peginterferon alfa-2a** (a pegylated recombinant human interferon stimulating an antiviral immune response), and a **nucleos(t)ide analog** (commonly entecavir or tenofovir, reverse transcriptase inhibitors that suppress HBV replication). This combination is under clinical investigation for the treatment of **chronic hepatitis B**, aiming to achieve functional cure (surface antigen loss)[1][3][2]. RO7445482 is being developed by Roche and Dicerna; peginterferon alfa-2a is marketed by Roche (brand name Pegasys).
- Brand names
- Pegasys
- Other names
- RG6346RG-6346RG 6346PEG-IFNnucleos(t)ide analog
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)HBV (Hepatitis B virus)
Beyond the preview
Go deeper on RO7445482 + peginterferon alfa-2a + nucleos(t)ide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7445482 + peginterferon alfa-2a + nucleos(t)ide.